Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk
Authors' conclusion
These findings support that higher vaspin levels are related to increased T2D risk and reduced gluteofemoral adiposity, positioning vaspin as a promising clinical predictor for T2D.
Study context
- Population
- Prospective Urban and Rural Epidemiology (PURE) biomarker substudy and Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial participantsPURE N = 10,052
- Exposure
- Per 1-SD increase in plasma vaspin
- Outcome
- Vaspin and T2D
Methodological detailstwo-sample Mendelian randomization, regression models
- Two-sample Mendelian randomization
- Regression models
Main finding
As reported in the abstract
Incident T2D per 1-SD vaspin increase (PURE), HR
1.16
95% CI 1.09–1.23P = 4.26 × 10-7
Prevalent T2D per 1-SD vaspin increase (ORIGIN), OR
1.16
95% CI 1.07–1.25P = 2.17 × 10-4
Observational data: associations, not effects.
Further findings
Vaspin change per 1-unit increase in BMI and TG (PURE)
- BMI: SD increase in vaspin
- 0.08 (95% CI 0.06-0.10; P = 2.04 × 10-15)
- TG: SD increase in vaspin
- 0.06 (95% CI 0.04-0.08; P = 4.08 × 10-13)
- Consistent associations in ORIGIN
Mendelian randomization (MR) analyses
- BMI-adjusted T2D risk per 1-SD vaspin, OR
- 1.01 (95% CI 1.00-1.02; P = 2.86 × 10-2)
- Vaspin SD increase per 1-SD decrease in genetic gluteofemoral adiposity
- 0.10 (95% CI 0.02-0.18; P = 2.01 × 10-2)
- No relationships between subcutaneous or visceral adiposity and vaspin
Original publication
Vaspin: A Novel Biomarker Linking Gluteofemoral Body Fat and Type 2 Diabetes Risk. Diabetes Care. Published 6 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →